#cdifficile
LightNews LightNews
narrowit.bsky.social
Lumen reports higher cure rates in a small Phase 2 C. difficile trial Lumen Bioscience reported positive top-line results from the Phase 2 RePreve trial of...

https://www.narrowit.com/news/lumen-lmn201-phase-2-c-difficile-results-2026-10-21
#LumenBioscience #LMN201 #CDifficile #ClinicalTrials
Lumen reports Phase 2 LMN-201 C. difficile results | Narrowit.com
Lumen says LMN-201 achieved an 83.3% global cure rate in a 23-patient randomized Phase 2 cohort, versus 36.4% for control.
www.narrowit.com
October 21, 2026 at 10:24 AM
purescience.news
Scientists discover a way to kill dangerous gut bacteria without killing the good #Science #Chemistry #MedicinalChemistry #cdifficile #gutbacteria #microbetreatment #naturalcompound #healthbreakthrough
Scientists discover a way to kill dangerous gut bacteria without killing the good
Scientists have discovered a natural compound that targets dangerous C. difficile bacteria without wiping out the gut's beneficial microbes. Successful early tests suggest it could lead to a gentler,...
purescience.news
October 20, 2026 at 3:47 PM
narrowit.bsky.social
Acurx Ended Q2 With $10.7 Million in Cash as Trial Spending Increased Acurx reported a $2.3 million quarterly loss, higher research spending and a larger cash...

https://www.narrowit.com/news/acurx-q2-cash-trial-financing-dilution-2026-08-16
#AcurxPharmaceuticals #ACXP #Ibezapolstat #CDifficile
Acurx Q2 Cash Rose as Trial Spending Increased | Narrowit.com
Acurx reported $10.7 million in cash, a $2.3 million Q2 loss and higher R&D spending as ibezapolstat development advanced.
www.narrowit.com
August 16, 2026 at 4:12 PM
c-metamorphosis.bsky.social
Hi guys first post on bluesky kinda nervous #shybacteria #cdifficile
April 25, 2026 at 11:20 PM
gastroadvisor.bsky.social
PCR-positive/toxin-negative results were linked to escalation of #IBD therapy, indicating that symptoms are often driven by underlying inflammation rather than active #CDifficile.
https://www.gastroenterologyadvisor.com/news/discordant-c-difficile-testing-predicts-ibd-therapy-escalation/
Discordant C difficile Testing Predicts IBD Therapy Escalation
Discordant C difficile tests in IBD predict therapy escalation, suggesting many cases reflect inflammation rather than true infection.
www.gastroenterologyadvisor.com
April 28, 2026 at 7:51 PM
bitscopic.bsky.social
Use of an AI-guided infection prevention bundle was associated with increased antimicrobial stewardship, with reduction in CDI incidence. www.hcplive.com/view/ai-tool...

#Cdifficile #CDI
AI Tool Shows Promise for Antimicrobial Stewardship, C Diff Prevention in Hospitals
Use of an AI-guided infection prevention bundle did not significantly reduce CDI incidence but was associated with increased antimicrobial stewardship.
www.hcplive.com
June 13, 2025 at 4:19 PM
bitscopic.bsky.social
A new study found that people with alcohol use disorder are much more likely to get a C. difficile infection. PraediAlert helps find both the infection and people with a history of alcohol problems.

www.infectioncontroltoday.com/view/uncover...

#Cdifficile #alcoholdisorder #Clostridioidesdifficile
Uncovering a Hidden Risk: Alcohol Use Disorder Significantly Increases C difficile Infection Rates
A groundbreaking study reveals a strong connection between alcohol use disorder and increased risk for Clostridioides difficile infection, challenging traditional assumptions and calling for enhanced ...
www.infectioncontroltoday.com
April 11, 2025 at 11:51 AM
pssalgado.bsky.social
🧫 #AMR #PhD open @newcastleuni.bsky.social!

How does #Cdifficile protein "armour" help it resist antimicrobials? Join me and @henrikstrahl.bsky.social to find out using:

🔬 #Structuralbiology, #microbiology #microscopy #genetics

📅 Deadline 20 May 2026

#PhD #PhDLife

Pls share!

(UK home only)
C. difficile S-layer’s role in antimicrobial resistance at Newcastle University on FindAPhD.com
PhD Project - C. difficile S-layer’s role in antimicrobial resistance at Newcastle University, listed on FindAPhD.com
findaphd.com
April 29, 2026 at 7:30 PM
pssalgado.bsky.social
A little intro: I'm scientist, researching an antibiotic-resistant human pathogen #Cdifficile using structural biology, biochemistry, microbiology, whatever helps answer the question. I normally talk about science, scicom, theatre, politics, geeky topics and occasionally on being a mum in #academia
July 25, 2023 at 1:28 PM
infect-net.bsky.social
👩‍⚕️👩🏾‍⚕️ Frauen in #Medizin & #Pharma: Connect & Collaborate! 🤝
Tillotts Pharma GmbH veranstaltet ein Netzwerk-Event speziell für euch:
📅 Mittwoch, 26. November 2025
🕟 18:30 Uhr
📍 Courtyard by Marriott Düsseldorf Hafen
Speditionstraße 11, 40221 Düsseldorf
#CDifficile #Vernetzung #Frauenkarrieren #Tillotts
October 28, 2025 at 10:46 AM
simonthelwall.bsky.social
Good write up of an outbreak of #cdifficile ribotype 955 here.
#hcai

www.gov.uk/government/p...
Emergence and outbreak of Clostridioides difficile ribotype 955 in England
www.gov.uk
December 5, 2025 at 5:31 PM
simonthelwall.bsky.social
It's worth noting that the CDRN surveillance is separate to the mandatory CDI surveillance and isolates should reflect those that are causing more severe diseases or outbreaks.
#hcai #cdifficile
October 6, 2024 at 6:23 AM
simonthelwall.bsky.social
Moving on to C. difficile infection, it's another story of years of success followed by a worrying rise in incidence in recent years.
#hcai #cdi #cdifficile
October 6, 2024 at 6:15 AM
femsjournals.bsky.social
Bile acids play a critical role in the germination of spores. Vinay et al. summarize the effects of #bile acids and their metabolites on #germination, receptor proteins, #germinants of clostridial species. #Cdifficile
@StanleyBrul
#FEMSMicrobiolRev
buff.ly/7Zh0ozL
March 7, 2025 at 10:00 AM
bnerlich.bsky.social
Last, weekend, outing for my post on 'phage and fiction' <a href="http://blogs.nottingham.ac.uk/makingsciencepublic/2018/08/23/phage-and-fiction/" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link" target="_blank" rel="noopener" data-link="bsky">http://blogs.nottingham.ac.uk/makingsciencepublic/2018/08/23/phage-and-fiction/ #bacteria #synbio #igemef="/hashtag/igem2018" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#igem2018 #igem #cdifficile
Phage and fiction - Making Science Public
We have known about bacteriophages for over a century. I myself became vaguely aware of them around 2004 when I started to be interested in bacteria and antimicrobial resistance and later on when my mother had Clostridium difficile, a health-care associated infection related to antibiotic use. However, I never actually looked more closely at phages until Carmen ...
blogs.nottingham.ac.uk
November 8, 2024 at 2:50 AM
contagionlive.bsky.social
A new study finds the most effective FMT strategy for C. difficile involves multiple-dose capsules or colonoscopy after extended antibiotic pretreatment, with repeated FMT for recurrences. @hcplivenews.bsky.social #IDsky #MEDsky #Cdifficile

Read more: www.contagionlive.com/view/study-e...
Study Explores Therapeutic Approaches to Enhance FMT Success in C difficile Treatment
The most successful FMT approach involved administering multiple-dose capsules or colonoscopy following an extended course of antibiotic pretreatment.
www.contagionlive.com
July 22, 2025 at 1:12 PM
contagionlive.bsky.social
📉 A new randomized trial found that oral vancomycin slightly reduced #Cdifficile recurrence in high-risk patients receiving systemic antibiotics, but the difference was not statistically significant, and VRE colonization increased. #IDsky #MEDsky

Read more: www.contagionlive.com/view/effecti...
Effectiveness of Oral Vancomycin in Preventing C diff Remains Uncertain after Trial
The role of oral vancomycin in preventing recurrence of C. difficile infection in at-risk persons receiving systemic antibiotic for non-CDI infection remains unclear after randomized trial.
www.contagionlive.com
July 7, 2025 at 1:11 PM
contagionlive.bsky.social
ICYMI: Hidden pathways of #Cdifficile transmission in hospitals; environmental contamination plays a key role in spreading the infection, suggesting a need for updated #infectioncontrol strategies focused on surface cleaning & hand hygiene. #IDsky #MEDsky

www.contagionlive.com/view/new-gen...
New Genomic Study Reveals Hidden Pathways of C difficile Transmission in Hospitals
Environmental contamination plays a larger role than previously recognized, prompting calls for updated infection control strategies
www.contagionlive.com
April 9, 2025 at 4:13 PM
contagionlive.bsky.social
Research in JAMA uncovers hidden pathways of #Cdifficile transmission in hospitals, emphasizing the need for stronger environmental cleaning & revised infection control strategies. #IDsky #MEDsky

Learn more about hospital surfaces playing a role in the spread: www.contagionlive.com/view/new-gen...
New Genomic Study Reveals Hidden Pathways of C difficile Transmission in Hospitals
Environmental contamination plays a larger role than previously recognized, prompting calls for updated infection control strategies
www.contagionlive.com
April 4, 2025 at 5:49 PM
contagionlive.bsky.social
In the first part of our interview with Dr. Larry Sutton CEO of LPOXY Therapeutics, we discuss SIDIPREV, an oxygen-based therapy designed to prevent #Cdifficile infections in high-risk patients. #CDiff #SIDIPREV #IDsky #MEDsky

Listen here: www.contagionlive.com/view/fightin...
Fighting C difficile Before It Starts: Lopoxy Therapeutics Approach
CEO Larry Sutton, MD, PhD, discusses SIDIPREV, a novel oxygen-based therapy aimed at preventing C difficile infections.
www.contagionlive.com
January 10, 2025 at 4:12 PM
contagionlive.bsky.social
LPOXY Therapeutics acquires assets to advance SIDIPREV™, a therapy to prevent #Cdifficile infections in antibiotic patients. #IDsky #MEDsky

CEO Dr. Larry Sutton discusses the science behind it. Stay tuned for our interview: www.contagionlive.com/view/lpoxy-t...
LPOXY Therapeutics Acquires Assets to Advance C difficile Protection for Antibiotic Patients
CEO Larry D Sutton, MD, PhD, elaborates on the company's strategy and the science behind SIDIPREV to prevent C difficile infections in hospitalized patients.
www.contagionlive.com
January 8, 2025 at 2:10 PM
contagionlive.bsky.social
The final part of our conversation with Dr. @joeyzacks.bsky.social discussed the challenges of community-acquired #Cdifficile. #IDsky #MEDsky

Listen here for deeper insights on this complicated infection and hope for it's possible #mRNAvaccine: www.contagionlive.com/view/while-h...
While Hospital-Acquired C difficile Cases Have Decreased, Community-Acquired Cases Have Risen
Contagion® is a fully integrated news resource for practitioners and specialists to assist with the identification, diagnosis, treatment, and prevention of infectious diseases.
www.contagionlive.com
December 18, 2024 at 4:31 PM
contagionlive.bsky.social
Dr. @joeyzacks.bsky.social discussed how current antibiotics disrupt the microbiome, but targeted vaccines may help break the cycle of recurrent #Cdifficile infections.
#mRNAVaccine #IDsky #MEDsky

Listen here for more insights and stay tuned for part 3 tmr: www.contagionlive.com/view/targeti...
Targeting the C Diff Pathogen and Its Immune-Suppressing Toxins
Joseph Zackular, PhD suggests that mRNA vaccines and monoclonal antibodies could offer more effective treatments for recurrent C difficile infections
www.contagionlive.com
December 17, 2024 at 2:22 PM
contagionlive.bsky.social
Dr. Joseph Zackular, from CHOP and UPenn discusses his mRNA vaccine research for #Cdifficile. The vaccine has shown promise in reducing mortality in animal models, with plans to move to human trials. #IDsky #MEDsky

Stay tuned for part 2 tomorrow: www.contagionlive.com/view/mrna-va...
mRNA Vaccine Shows Potential for C difficile Infections
Joseph Zackular, PhD, shares insights on his team’s mRNA vaccine research for C difficile, highlighting progress in animal models and future plans for human trials.
www.contagionlive.com
December 16, 2024 at 7:47 PM
smitslab.bsky.social
Our work focuses on ibezapolstat (for treatment of #Cdifficile infections #CDI) and a novel compound from a series that is intended to target other pathogens, such as #VRE and #MRSA. This representative compound, ACX-801, was selected on the basis of excellent inhibition of PolC in vitro. 4/9
November 6, 2025 at 10:32 AM